B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Otsuka Holdings CO ADR (OP:OTSKY)

35.41 -0.02 (-0.06%)
Streaming Delayed Price Updated: 3:53 PM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Otsuka Holdings CO ADR

News headline image
Why Axsome Therapeutics Stock Jumped Over 20% in April ↗
Axsome shares reached an all-time high last month, and there might be more to come. 
Via The Motley Fool
News headline image
Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market ↗
Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment. 
Via Benzinga
News headline image
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results ↗
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025. 
Via Benzinga
News headline image
OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q2 2024 ↗
Otsuka Holdings just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q1 2024 ↗
Otsuka Holdings just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study ↗
 
Via Benzinga
News headline image
Why Are Akebia Therapeutics Shares Falling Today? ↗
 
Via Benzinga
News headline image
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia ↗
 
Via Benzinga
News headline image
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation ↗
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo. 
Via Benzinga
News headline image
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo ↗
IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed. 
Via Benzinga
News headline image
Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension ↗
Medtronic Plc (NYSE: MDT) says the FDA Circulatory System Devices Panel (CSDP) voted unanimously (13-0) on safety and in favor (7-6) of the effectiveness of the Symplicity blood pressure procedure,  
Via Benzinga
News headline image
Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device ↗
The FDA's Circulatory Systems Devices Panel of the Medical Devices Advisory Committee backed Recor Medical Inc and its parent company, Otsuka Medical Devices Co Ltd's 
Via Benzinga
News headline image
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation ↗
Otsuka Pharmaceutical Co Ltd (OTC: OTSKF) (OTC: OTSKY) (Otsuka) and H. 
Via Benzinga
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches ↗
Approximately 160,000 individuals in the United States are diagnosed with polycystic kidney disease, and the global prevalence of the condition is estimated at between 4 million and 7 million people. 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry? ↗
One very large drug multinational has already been active in writing checks to finance drug development in the psychedelic drug industry. 
Via Talk Markets
News headline image
4 Pre-Merger SPACs to Buy That Are Poised to Soar ↗
From quantum computing to energy storage, these four SPACs' merger partners could prove to be quite disruptive over the longer term. 
Via InvestorPlace
Topics Electric Vehicles
News headline image
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia ↗
Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat... 
Via Benzinga
News headline image
3 Cheap Pharmaceutical Stocks to Grab Now ↗
The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.